Zhang Limin, Su Jin, Wu Xiaozheng, Chen Yunzhi, Li Wen
Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
Medicine (Baltimore). 2025 Jan 31;104(5):e41317. doi: 10.1097/MD.0000000000041317.
Asthma seriously affects people's survival and quality of life, causing a huge economic burden on society. Modern clinical use of Qianjinweijing Decoction (QJWJ) for the treatment of asthma has achieved good results. However, there is still a lack of research on its efficacy and mechanism of action. Therefore, the purpose of this study is to evaluate the efficacy of QJWJ in the treatment of asthma by systematic review and meta-analysis, and to explore its potential mechanism by network pharmacology.
The meta-analysis was performed to search for studies published before May 2023 in 7 databases, and Revman 5.4 and R language softwares were used for analysis. Network pharmacology was based on open databases and softwares such as Cytoscape, Perl, Autoduck Vina, and R language.
A total of 14 studies were included, involving 1200 patients. The results of the meta-analysis showed that QJWJ could significantly improve the clinical efficacy of asthma patients compared with routine pharmacotherapy (risk ratio = 1.22, 95% CI [1.16, 1.28], P < .00001), enhance lung function, such as FEV1/FVC (mean difference [MD] = 5.63, 95% CI [1.45, 9.81], P = .008), FEV1% (MD = 5.03, 95% CI [4.32, 5.74], P < .00001), PEF (standardized mean difference = 1.37, 95% CI [1.03, 1.71], P < .00001), and increase traditional Chinese medicine syndrome score (MD = -2.50, 95% CI [-4.81, -0.19], P = .03). The results of network pharmacology suggested that the 4 traditional Chinese medicines in QJWJ included 35 active ingredients and 34 potential targets for the treatment of asthma. The core ingredients involved were stigmasterol, β-sitosterol, hederagenin, and gibberellin 7. The core targets were PTGS2, BCL2, and CASP3. The interaction pathway between QJWJ and asthma was mainly enriched in p53, cyclic guanosine monophosphate-protein kinase G, IL-17, and advanced glycation end products-receptor for advanced glycation end products signaling pathways. Molecular docking showed that the core ingredients had good binding activity with the core targets.
QJWJ is effective in the treatment of asthma, and the therapeutic mechanism may be related to its regulation of inflammation, immunity, and apoptosis.
哮喘严重影响人们的生存和生活质量，给社会带来巨大经济负担。现代临床应用千金苇茎汤治疗哮喘取得了良好效果。然而，其疗效及作用机制仍缺乏研究。因此，本研究旨在通过系统评价和荟萃分析评估千金苇茎汤治疗哮喘的疗效，并通过网络药理学探索其潜在机制。
进行荟萃分析，检索7个数据库中2023年5月前发表的研究，使用Revman 5.4和R语言软件进行分析。网络药理学基于Cytoscape、Perl、Autoduck Vina和R语言等开放数据库和软件。
共纳入14项研究，涉及1200例患者。荟萃分析结果显示，与常规药物治疗相比，千金苇茎汤可显著提高哮喘患者的临床疗效（风险比=1.22，95%置信区间[1.16，1.28]，P<.00001），增强肺功能，如FEV1/FVC（平均差[MD]=5.63，95%置信区间[1.45，9.81]，P=.008）、FEV1%（MD=5.03，95%置信区间[4.32，5.74]，P<.00001）、PEF（标准化平均差=1.37，95%置信区间[1.03，1.71]，P<.00001），并提高中医证候评分（MD=-2.50，95%置信区间[-4.81，-0.19]，P=.03）。网络药理学结果表明，千金苇茎汤中的4味中药包含35种活性成分和34个治疗哮喘的潜在靶点。核心成分包括豆甾醇、β-谷甾醇、常春藤皂苷元、赤霉素7。核心靶点为PTGS2、BCL2和CASP3。千金苇茎汤与哮喘之间的相互作用途径主要富集在p53、环磷酸鸟苷-蛋白激酶G、IL-17和晚期糖基化终产物-晚期糖基化终产物受体信号通路。分子对接显示核心成分与核心靶点具有良好的结合活性。
千金苇茎汤治疗哮喘有效，其治疗机制可能与其对炎症、免疫和凋亡的调节有关。
